Table II.

Influence of HSP90 mRNA expression on the prognosis of non-small cell lung cancer patients with the clinical stage of I (n=577), II (n=244) and III (n=70).

Gene/clinical stage	HR	95% CI	P-value
HSP90AA1
I	1.56	1.29–1.88	2.70×10−6
II	1.18	0.82–1.71	0.38
III	1.02	0.58–1.79	0.94
HSP90AB1
I	3.28	2.29–4.7	7.40×10−12
II	1.66	1.04–2.66	0.033
III	1.34	0.64–2.79	0.44
HSP90B1
I	1.86	1.40–2.47	1.5×10−5
II	1.1	0.76–1.59	0.61
III	0.92	0.54–1.59	0.78
TRAP1
I	0.83	0.63–1.09	0.17
II	1.14	0.79–1.65	0.48
III	0.68	0.39–1.17	0.16

TRAP1, tumor necrosis factor receptor-associated protein 1; HSP, heat shock protein; HR, hazard ratio; CI, confidence interval